Overview

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

Status:
Active, not recruiting

Trial end date:
2022-07-27

Target enrollment:

Participant gender:

Summary

An open-label study to assess the PK of estradiol, estrone and progesterone from the DARE-HRT1 intravaginal rings at two different dose strengths.

Phase:

Phase 1

Details

Lead Sponsor:

Daré Bioscience, Inc.